The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Nature, Published online: 30 October 2019; doi:10.1038/s41586-019-1694-1
Treatment of KRASG12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG 510 could be effective in patients for whom treatments are currently lacking.
Comments
Post a Comment